查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598430

溶栓药物市场：按类型、类别和分销管道划分 - 全球预测 2025-2030

Thrombolytic Drug Market by Types (Fibrin Specific Drugs, Nonfibrin-Specific Drugs), Category (Abbokinase, Eminase, RETAVASE), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年溶栓药物市场价值为12.2亿美元，预计2024年将达到14.3亿美元，复合年增长率为17.74%，到2030年将达到38.3亿美元。

溶栓剂（溶栓剂）溶解血管中危险的血栓，改善血流并防止组织和器官损伤。需求主要在于其在治疗急性心肌梗塞、缺血性中风和肺动脉栓塞方面具有挽救生命的潜力。这项重要的医疗应用也扩展到医院、诊所和急救服务，在这些地方，快速清除血栓至关重要。根据市场洞察，心血管疾病的增加和医疗基础设施的进步正在推动这一成长。此外，配方技术的改进提高了功效和安全性，从而导致更广泛的采用。然而，市场面临挑战，包括高昂的治疗成本、潜在的副作用以及需要熟练的专业人员安全有效地管理这些药物。如果没有可靠的报销结构或明确的成本效益证据，医院和医疗保健系统可能不愿意投资昂贵的治疗，这可能成为市场扩张的主要障碍。

主要市场统计
基准年[2023] 12.2亿美元
预测年份 [2024] 14.3亿美元
预测年份 [2030] 38.3亿美元
复合年增长率（%） 17.74%

开发更具针对性的溶栓剂、副作用更少和起效更快的製剂，可以更有效地缓解危急情况，具有很大的潜力。透过奈米技术等创新的给药方法以及探索这些药物治疗其他闭塞性和血管疾病的用途，还有扩大应用的潜力。专注于改进给药技术（例如最大限度地减少副作用和简化给药计划）的研究的公司将获得竞争优势。同时，与公共卫生机构合作以提高及时溶栓干预的意识可能会刺激市场需求。儘管受到严格法规和竞争格局的限制，但竞争格局可以利用新技术来应对当前挑战并探索重大创新。总体而言，市场扩张强劲，但解决系统性医疗保健障碍并专注于研究创新对于未来的成长和永续性至关重要。

市场动态：揭示快速发展的溶栓市场的关键市场洞察

供需的动态交互作用正在改变溶栓药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 提高患者对纤溶治疗的认识
    • 肾臟疾病、中风和高血压的盛行率飙升
    • 有利的药品报销方案
  • 市场限制因素
    • 药物和治疗费用上涨
  • 市场机会
    • 治疗技术的进步和零售药局的增加
    • 增加医疗支出和增加协作活动
  • 市场挑战
    • 严格的药品监管体系

波特五力：驾驭溶栓药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解溶栓药物市场的外部影响

外部宏观环境因素在塑造溶栓药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解溶栓药物市场的竞争格局

对溶栓药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵溶栓药物市场供应商绩效评估

FPNV 定位矩阵是评估溶栓药物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，以规划溶栓药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，溶栓药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高患者对纤溶治疗的认识
      • 肾臟疾病、中风和高血压的发生率飙升
      • 有利的药品报销方案
    • 抑制因素
      • 药物和治疗费用高昂
    • 机会
      • 治疗技术进步与零售药局的兴起
      • 医疗费用增加和关节活动增加
    • 任务
      • 严格的药品管制制度
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章溶栓药物市场：依类型

  • 纤维蛋白特异性药物
  • 非纤维蛋白特异性药物

第七章溶栓药物市场：依类别

  • 阿沃激酶
  • 埃米纳酶
  • 丽塔贝斯
  • 链霉酶
  • TNK酶

第八章溶栓药物市场：按分销管道

  • 网路药局
  • 医院药房
  • 零售药房

第九章美洲溶栓市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太溶栓药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲溶栓药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Becton, Dickinson and Company（BD）
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Chiesi Farmaceutici SPA
  • Eli Lilly and Company
  • Medtronic PLC
  • Microbix Biosystems, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Sigma-Aldrich Corporation
  • Synergy Medical Inc
  • Taj Pharmaceuticals Ltd.
  • Teleflex Incorporated
Product Code: MRR-43286DA07EA6

The Thrombolytic Drug Market was valued at USD 1.22 billion in 2023, expected to reach USD 1.43 billion in 2024, and is projected to grow at a CAGR of 17.74%, to USD 3.83 billion by 2030.

Thrombolytic drugs, or clot busters, dissolve dangerous clots in blood vessels, improving blood flow and preventing damage to tissues and organs. Their necessity lies in their life-saving potential, primarily in treating acute myocardial infarction, ischemic stroke, and pulmonary embolism. This critical medical application extends to hospitals, clinics, and emergency services where rapid clot resolution is imperative. Market insights reveal growth driven by increasing incidences of cardiovascular diseases and advancements in healthcare infrastructure. Additionally, technological improvements in drug formulation enhance efficacy and safety profiles, encouraging broader adoption. However, the market faces challenges, including high therapy costs, potential side effects, and the requirement for skilled professionals to administer these drugs safely and efficiently. Hospitals and healthcare systems may be reluctant to invest in expensive treatments without solid reimbursement structures or clear evidence of cost-effectiveness, which can be a significant hurdle in market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 1.22 billion
Estimated Year [2024] USD 1.43 billion
Forecast Year [2030] USD 3.83 billion
CAGR (%) 17.74%

Opportunities abound in the development of more targeted thrombolytic agents with fewer side effects or rapid-acting formulations that could alleviate time-critical conditions more effectively. There is also potential in expanding applications through innovative delivery methods such as nanotechnology or exploring these drugs' use in combating other blockages or vascular diseases. Companies focusing on research to minimize adverse reactions and improve administration techniques, such as easier dosing schedules, could gain a competitive edge. Meanwhile, partnerships with public health entities to raise awareness about timely thrombolytic intervention might stimulate market demand. Although limited by stringent regulations and competitive landscapes, the thrombolytic drug market can explore significant innovation by addressing present challenges and harnessing emerging technologies. Overall, while market expansion is robust, addressing systemic healthcare barriers and emphasizing research innovations are vital for future growth and sustainability.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thrombolytic Drug Market

The Thrombolytic Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing patient awareness regarding fibrinolytic therapy
    • Surge in prevalence of kidney diseases, stroke, and hypertension
    • Favorable reimbursement scenario for the drugs
  • Market Restraints
    • High cost of the medicines and treatment
  • Market Opportunities
    • Technological advancements in the treatment and increasing number of retail pharmacies
    • Growing healthcare expenditure and rise of collaborative activities
  • Market Challenges
    • Strict drug regulatory systems

Porter's Five Forces: A Strategic Tool for Navigating the Thrombolytic Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thrombolytic Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thrombolytic Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thrombolytic Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thrombolytic Drug Market

A detailed market share analysis in the Thrombolytic Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thrombolytic Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thrombolytic Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thrombolytic Drug Market

A strategic analysis of the Thrombolytic Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thrombolytic Drug Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Becton, Dickinson and Company (BD), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.P.A., Eli Lilly and Company, Medtronic PLC, Microbix Biosystems, Inc., Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Sigma-Aldrich Corporation, Synergy Medical Inc, Taj Pharmaceuticals Ltd., and Teleflex Incorporated.

Market Segmentation & Coverage

This research report categorizes the Thrombolytic Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Types, market is studied across Fibrin Specific Drugs and Nonfibrin-Specific Drugs.
  • Based on Category, market is studied across Abbokinase, Eminase, RETAVASE, Streptase, and TNKase.
  • Based on Distribution Channel, market is studied across Electronic Pharmacy, Hospital Pharmacy, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing patient awareness regarding fibrinolytic therapy
      • 5.1.1.2. Surge in prevalence of kidney diseases, stroke, and hypertension
      • 5.1.1.3. Favorable reimbursement scenario for the drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the medicines and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the treatment and increasing number of retail pharmacies
      • 5.1.3.2. Growing healthcare expenditure and rise of collaborative activities
    • 5.1.4. Challenges
      • 5.1.4.1. Strict drug regulatory systems
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thrombolytic Drug Market, by Types

  • 6.1. Introduction
  • 6.2. Fibrin Specific Drugs
  • 6.3. Nonfibrin-Specific Drugs

7. Thrombolytic Drug Market, by Category

  • 7.1. Introduction
  • 7.2. Abbokinase
  • 7.3. Eminase
  • 7.4. RETAVASE
  • 7.5. Streptase
  • 7.6. TNKase

8. Thrombolytic Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Electronic Pharmacy
  • 8.3. Hospital Pharmacy
  • 8.4. Retail Pharmacies

9. Americas Thrombolytic Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Thrombolytic Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Thrombolytic Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Becton, Dickinson and Company (BD)
  • 3. Boehringer Ingelheim International GmbH
  • 4. Boston Scientific Corporation
  • 5. Chiesi Farmaceutici S.P.A.
  • 6. Eli Lilly and Company
  • 7. Medtronic PLC
  • 8. Microbix Biosystems, Inc.
  • 9. Pfizer, Inc.
  • 10. Sanofi S.A.
  • 11. Siemens Healthineers AG
  • 12. Sigma-Aldrich Corporation
  • 13. Synergy Medical Inc
  • 14. Taj Pharmaceuticals Ltd.
  • 15. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. THROMBOLYTIC DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. THROMBOLYTIC DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THROMBOLYTIC DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THROMBOLYTIC DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THROMBOLYTIC DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THROMBOLYTIC DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN SPECIFIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY NONFIBRIN-SPECIFIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ABBOKINASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY EMINASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RETAVASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY STREPTASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TNKASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ELECTRONIC PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. THROMBOLYTIC DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. THROMBOLYTIC DRUG MARKET, FPNV POSITIONING MATRIX, 2023